DrugPatentWatch Database Preview
SLYND Drug Profile
Try a free trialSee Plans and Pricing
Which patents cover Slynd, and what generic alternatives are available?
Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA.
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. Additional details are available on the drospirenone profile page.
Summary for SLYND
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | SLYND at DailyMed |
Generic Entry Opportunity Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for SLYND
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
